Table 4.

CPNDS (2014) Recommendations for Carbamazepine and HLA Genotype.

GenotypeRecommendation 1.1
HLA-B*15:02 Genetic testing for HLA-B*15:02 is recommended for all CBZ-naive patients before initiation of CBZ therapy (Level A – strong in patients originating from populations where HLA-B*15:02 is common, its frequency unknown or whose origin is unknown; Level C – optional in patients originating from populations where HLA-B*15:02 is rare).
HLA-A*31:01 Genetic testing for HLA-A*31:01 is recommended for all CBZ-naive patients before initiation of CBZ therapy (Level B – moderate in all patients; Table 7).

CBZ: Carbamazepine.
Please see Therapeutic Recommendations based on Genotype for the all the recommendations from CPNDS, and the grading scheme used for the level of evidence. Table is adapted from (5).

From: Carbamazepine Therapy and HLA Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.